Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed
Wednesday, 03 November, 2010
California-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer.
The three separate trials, which have begun enrollment, are targeting patients pancreatic cancer, advanced colorectal cancer, and non-squamous non-small cell lung cancer (NSCLC).
OncoMed's treatments use monoclonal antibodies to target specific biologic pathways that are critical to tumour initiating cells, or so-called 'cancer stem cells'.
The trials will be run in Australia and New Zealand through the Sydney-based contract research organisation, Novotech.
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
